From: Therapeutic potential of heterocyclic pyrimidine scaffolds
Compounds | Volume of edema (ml)a | ED50 (mg/kg) | |||
---|---|---|---|---|---|
0 | 1Â h | 2Â h | 4Â h | ||
e5 | 0.31 ± 0.01 | 0.44 ± 0.02b (38)c | 0.49 ± 0.01b (43) | 0.52 ± 0.02b (52) | 23.45d |
e6 | 0.35 ± 0.02 | 0.46 ± 0.01b (47) | 0.50 ± 0.01b (53) | 0.54 ± 0.02b (56) | 28.15 |
e7 | 0.33 ± 0.02 | 0.46 ± 0.01b (42) | 0.53 ± 0.01b (37) | 0.59 ± 0.02b (40) | 26.12 |
Control | 0.32 ± 0.01 | 0.55 ± 0.01 | 0.64 ± 0.02 | 0.76 ± 0.01 | – |
Diclofenac | 0.32 ± 0.02 | 0.45 ± 0.01b (38) | 0.50 ± 0.02b (43) | 0.53 ± 0.02b (52) | 25.13 |